Sitagliptin, a selective DPP‐4 inhibitor for increasing the half‐life of endogenous GLP‐1 and stimulating GLP‐1 receptor,18 is approved in more than 130 countries worldwide for the treatment of adult patients with type 2 diabetes (T2D).19 Here, GLP1R is linked to type 2 diabetes mellitus.